• Quest is on for Meaningful Outcome Measures for Anti-Obesity Drugs

    Jan 23 | Diagnostics World News | A lot is at stake in obesity drug development, heightening the focus of pharma sponsors on producing the right evidence to support a label claim and differentiating their products in the rapidly growing weight management pharmacotherapy market. It’s also the rationale for the industrywide DECODE Obesity initiative of Ametris (formerly ActiGraph) looking to expand the range of outcome measures beyond weight loss. More

  • Illumina Announces CMS Reimbursement for IVD Oncology Test

    Jan 21 | Diagnostics World News | Illumina has announced CMS reimbursement for TruSight Oncology Comprehensive. The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test. The news comes just a week after presenting a clinical-focused vision and strong Q4 results at the J.P. Morgan Healthcare Conference. More

  • Extracellular Vesicles Mapping Molecular Blueprints

    Jan 20 | Diagnostics World News | There can be little debate that Alzheimer’s disease is one of the greatest healthcare challenges we face globally. Most recent estimates suggest that over 57 million people worldwide are living with dementia, of which 70% is caused by Alzheimer’s. With aging societies, this number is expected to increase to over 150 million by 2050. Yet there is a growing sense of impending change, particularly because the way we diagnose Alzheimer’s is now at a pivotal moment. More

  • Diagnostics Trends: Diagnostic Foundation Models, Expanded Genetic Testing, Lots of MRD

    Jan 16 | Diagnostics World News | Grail returned to the 44th Annual J.P. Morgan Healthcare Conference for its second appearance as an independent public company, and CEO Bob Ragusa had positive momentum to report, though the tipping point is still expecting mid-2026 with the readouts of two major clinical trials. The multi-cancer early detection company is closing in on a critical regulatory milestone while demonstrating strong commercial traction. More

  • Protein Signature May Provide Early Warning on Morality Risk

    Jan 14 | Diagnostics World News | Researchers in the University of Surry (UK) have identified a set of blood-based protein signals that may foreshadow an individual’s risk of death five to 10 years before it occurs. This discovery carries promise for next-generation diagnostics aimed at early risk detection rather than disease diagnosis. More

  • Grail at JPM 2026: Commercial Momentum Builds as FDA Filing Looms

    Jan 12 | Diagnostics World News | Grail returned to the 44th Annual J.P. Morgan Healthcare Conference for its second appearance as an independent public company, and CEO Bob Ragusa had positive momentum to report, though the tipping point is still expecting mid-2026 with the readouts of two major clinical trials. The multi-cancer early detection company is closing in on a critical regulatory milestone while demonstrating strong commercial traction. More

  • Recent Advances in Alzheimer's Disease Diagnostics

    Jan 09 | Diagnostics World News | There can be little debate that Alzheimer’s disease is one of the greatest healthcare challenges we face globally. Most recent estimates suggest that over 57 million people worldwide are living with dementia, of which 70% is caused by Alzheimer’s. With aging societies, this number is expected to increase to over 150 million by 2050. Yet there is a growing sense of impending change, particularly because the way we diagnose Alzheimer’s is now at a pivotal moment. More

  • Pair of Brainwave-Tracking Earbuds Making Waves at CES

    Jan 08 | Diagnostics World News | In just a few years, the monitoring of brain signals via ubiquitous earbuds will be as common as heart rhythm tracking by popular smartwatch brands like Apple and Fitbit. People wearing these next-generation earbuds will have their electroencephalogram (EEG) effortlessly analyzed while they listen to music or make phone calls. More

  • EverythingALS Taps ‘Power in the Crowd’ to Revamp Research Norms

    Jan 07 | Diagnostics World News | After less than three years of collecting voice samples from individuals with amyotrophic lateral sclerosis, and a control group of healthy volunteers, the Peter Cohen Foundation awaits approval from the Food and Drug Administration of its algorithm as a secondary biomarker for tracking the progression of the devastating neurological disease. The drug development tool, a “listener effort” prediction model, will be used in a multitude of clinical trials as soon as the first quarter of 2026. More

  • Trendspotting: Precision Diagnostics, Artificial Intelligence, Data Management, Collection

    Jan 06 | Diagnostics World News | To kick off 2026, we spoke with industry experts and leaders in the Diagnostics World community about what they expect and look forward to in the new year. Here are the full trends and predictions, including more on AI, data management and collection, precision diagnostics, new testing, and more. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more